1 July 2025

Physiomics plc

("Physiomics" or the "Company")

Contract Award

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a new contract award with an existing client.

In this new project, Physiomics will apply PK/PD modelling and simulation expertise to support preclinical-to-clinical translation for one of the client's lead candidates and inform selection of human dosing schemes for a First in Human clinical trial.

This contract, which supports the development of a non-oncology therapeutic, highlights the value of Physiomics' integrated modelling and simulation approach across the drug development lifecycle - from early discovery through translational planning and into clinical development. The contract is valued at £98,600 and will be delivered over the next 18 months.  

Dr Peter Sargent, CEO of Physiomics, commented:

"We are delighted to continue partnering with this client and announce this follow on work with their team. Working with them from early discovery through to clinical planning enables us to add deeper insights into their experimental and clinical trial design, helping them accelerate this promising drug development programme." 

For more information about Physiomics and its services, please visit www.physiomics.co.uk.

Enquiries:

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

Notes to Editor

About Physiomics

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.